PEA cream to protect skin!
Treatment of atopic dermatitis has always been a tremendous problem. Treatment with corticosteroids only inhibit the inflammation of the skin and do not bring the skin in balance. On the contrary. After weeks of treatment, the skin loses its elasticity and becomes old and wrinkled and easily bruised. That is not what you expect from a treatment. Now the treatment insights of doctors can shift from symptom control to balancing overactive inflammations as in atopic dermatitis and repair of the skin barrier function.
Furthermore, with the availability of palmitoylethanolamide cream (PEA cream) the skin can also be extra protected by the reintegration of water in the skin via physiologic moisturizers, available in PEA cream. PEA cream with the PEA-opt® quality mark stands for quality, purity and for a standardized and patented production process.
Most importantly for the vehicle of the PEA cream is that it reduces transepidermal water loss, hand in hand with calming the inflammation via the active principle PEA.
Skin barrier defects in atopic dermatitis include increased stratum corneum chymotryptic enzyme, increased proteases, decreased maturation of lamellar bodies, and decreased filaggrin. Palmitamide MEA (PEA) is an important component of The PEA cream and it is a reparative fatty amide with anti-inflammatory and protective properties.
Researching the effect of PEA on atopic patients
Some years ago, dermatologists conducted a PEA study in which atopic patients applied PEA and a neutral cream to their left wrist and forearm, and the neutral cream only to their right wrist and arm. After 2 weeks of treatment, the difference was already clear.
These results lead to a full scale big international study, including more than thousands of patients suffering from atopic eczema, aged 2-70, all treated with PEA cream. Itching, erythema, scaling, dryness, wrinkling and skin damages after treatment with PEA cream significantly improved or was eliminated, compared to the state without PEA cream.
For children, it is important that itching was reduced, in this way PEA cream stops children suffering from eczema from itching and scratching, and the skin will get time to heal. The skin reparative properties of PEA are quite significant and has been proven in a number of studies, also in pet animals suffering from skin diseases.
More and more data emerge, supporting the efficacy of molecules such as PEA in skin disorders. Researchers and dermatologists reported that topical application of PEA based cream reduced uremic pruritus. Dry skin on hemodialysis patients was completely eliminated after a three week period of twice daily applications of the cannabinoid cream. The itching was significantly reduced in eighty-one percent of the subjects. Encouraging results for PEA cream!
References PEA cream
Kircik L. A nonsteroidal lamellar matrix cream containing palmitoylethanolamide for the treatment of atopic dermatitis. J Drugs Dermatol. 2010 Apr;9(4):334-8.
Phan NQ, Siepmann D, Gralow I, Ständer S. Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. J Dtsch Dermatol Ges. 2010 Feb;8(2):88-91. doi: 10.1111/j.1610-0387.2009.07213.x. Epub 2009 Sep 10.
Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study).
J Eur Acad Dermatol Venereol. 2008 Jan;22(1):73-82. doi: 10.1111/j.1468-3083.2007.02351.x.
Kemeny L, Koreck A, Kis K, Kenderessy-Szabo A, Bodai L, Cimpean A, Paunescu V, Raica M, Ghyczy M. Endogenous phospholipid metabolite containing topical product inhibits ultraviolet light-induced inflammation and DNA damage in human skin. Skin Pharmacol Physiol. 2007;20(3):155-61. Epub 2007 Jan 17.
Ständer S, Reinhardt HW, Luger TA. [Topical cannabinoid agonists. PEA, an effective new possibility for treating chronic pruritus]. Hautarzt. 2006 Sep;57(9):801-7. German.
Szepietowski JC, Szepietowski T, Reich A. Efficacy, and tolerance of PEA cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat. 2005;13(2):97-103.
Abramo F, Campora L, Albanese F, della Valle MF, Cristino L, Petrosino S, Di Marzo V, Miragliotta V. Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis. BMC Vet Res. 2014 Jan 14;10:21. doi: 10.1186/1746-6148-10-21.